Last reviewed · How we verify
NCT05775549: FLAME
A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer
trial testing None (Observational Study) in Advanced Ovarian Cancer in 24 participants. Completed in 27 October 2023.
27 October 2023
Quick facts
| Lead sponsor | AstraZeneca |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 24 |
| Start date | 10 July 2023 |
| Primary completion | 27 October 2023 |
| Estimated completion | 27 October 2023 |
| Sites | 7 locations across United States |
Drugs / interventions tested
- None (Observational Study)
Conditions studied
- Advanced Ovarian Cancer — all drugs for Advanced Ovarian Cancer →
Sponsor
AstraZeneca — full company profile →
Who can join
Adults 18 to 130, female only, with Advanced Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will collect the data from existing patient medical records at US cancer centers. The study will include patients with BRCAwt ovarian cancer who have been prescribed first line (1L) olaparib maintenance treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05775549
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of None (Observational Study)
Trials testing the same drug.
- NCT07368465 — Determinant Factors in Excessive Gestational Weight Gain: Physical Activity, Nutritional Status, and Anxiety · recruiting
- NCT06618430 — Evaluation Of DNA Methylation Pattern In Healthy, Sarcopenic, Obese And Sarcopenic Obese Older Women: A Cross-Sectional · active not recruiting
- NCT06192004 — Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy Wit · terminated
- NCT05592483 — An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic B · terminated
- NCT05677139 — A Study for Observing Severe Asthma in Patients Treated With Tezepelumab · completed
Other recruiting trials for Advanced Ovarian Cancer
Currently open trials in the same condition.
- NCT06997029 — A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors · Phase 1 · recruiting
- NCT06940921 — SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases · Phase 1, PHASE2 · active not recruiting
- NCT04862325 — SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS · NA · active not recruiting
- NCT04065009 — The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer · Phase 3 · active not recruiting
- NCT03737643 — Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab a · Phase 3 · active not recruiting
Other AstraZeneca trials
Trials by the same sponsor.
- NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
- NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
- NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
- NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
- NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05775549 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
- Last refreshed: 20 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05775549.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing